Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study

被引：20

作者：

Kohler, Philipp ^{[1
]}

Gusewell, Sabine ^{[2
]}

Seneghini, Marco ^{[1
]}

Egger, Thomas ^{[1
]}

Leal, Onicio ^{[3
,4
]}

Brucher, Angela ^{[5
]}

Lemmenmeier, Eva ^{[6
]}

Moller, J. Carsten ^{[7
]}

Rieder, Philip ^{[8
]}

Ruetti, Markus ^{[9
]}

Stocker, Reto ^{[8
]}

Vuichard-Gysin, Danielle ^{[10
]}

Wiggli, Benedikt ^{[11
]}

Besold, Ulrike ^{[12
]}

Kuster, Stefan P. ^{[13
]}

McGeer, Allison ^{[14
]}

Risch, Lorenz ^{[15
,16
,17
]}

Friedl, Andree ^{[11
]}

Schlegel, Matthias ^{[1
]}

Vernazza, Pietro ^{[1
]}

Kahlert, Christian R. ^{[1
,18
]}

机构：

[1] Cantonal Hosp St Gallen, Div Infect Dis, Hosp Epidemiol, Rorschacherstr 95, CH-9007 St Gallen, Switzerland

[2] Cantonal Hosp St Gallen, Clin Trials Unit, St Gallen, Switzerland

[3] Epitrack, Recife, Brazil

[4] Univ Zurich, Dept Econ, Zurich, Switzerland

[5] Psychiat Serv, St Gallen South, Canton, Switzerland

[6] Clienia Littenheid AG, Private Clin Psychiat & Psychotherapy, Littenheid, Switzerland

[7] Ctr Neurol Rehabil, Zihlschlacht, Switzerland

[8] Hirslanden Clin, Zurich, Switzerland

[9] Fuerstenland Toggenburg Hosp Grp, Wil, Switzerland

[10] Thurgau Hosp Grp, Div Infect Dis, Hosp Epidemiol, Munsterlingen, Switzerland

[11] Cantonal Hosp Baden, Div Infect Dis, Hosp Epidemiol, Baden, Switzerland

[12] Geriatr Clin St Gallen, St Gallen, Switzerland

[13] Federal Off Publ Hlth, Bern, Switzerland

[14] Sinai Hlth Syst, Toronto, ON, Canada

[15] Labormed Zent Dr Risch, Schaan, Liechtenstein

[16] Clienia Littenheid AG, Private Clin Psychiat & Psychotherapy, Littenheid, Switzerland

[17] Univ Bern, Univ Inst Clin Chem, Ctr Lab Med, Inselspital, Bern, Switzerland

[18] Childrens Hosp Eastern Switzerland, Div Infect Dis, Hosp Epidemiol, St Gallen, Switzerland

来源：

BMC MEDICINE | 2021年 / 19卷 / 01期

基金：

瑞士国家科学基金会;

关键词：

COVID-19; Surveillance; Re-infection; Healthcare workers; POPULATION-LEVEL;

D O I：

10.1186/s12916-021-02144-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus. Methods Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with coronavirus disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies. Results A total of 4812 HCW participated, wherein 144 (3%) were seropositive at baseline. We analyzed 107,807 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P = 0.83) between those with and without positive baseline serology. Among 2712 HCW with >= 1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2645 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95% CI 0.15-0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95% CI 0.39-0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95% CI 0.49-0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results. Conclusions Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least 8 months.

引用

页数：10

共 28 条

[1] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy [J].

Abu-Raddad, Laith J. ;

Chemaitelly, Hiam ;

Coyle, Peter ;

Malek, Joel A. ;

Ahmed, Ayeda A. ;

Mohamoud, Yasmin A. ;

Younuskunju, Shameem ;

Ayoub, Houssein H. ;

Al Kanaani, Zaina ;

Al Kuwari, Einas ;

Butt, Adeel A. ;

Jeremijenko, Andrew ;

Kaleeckal, Anvar Hassan ;

Latif, Ali Nizar ;

Shaik, Riyazuddin Mohammad ;

Rahim, Hanan F. Abdul ;

Nasrallah, Gheyath K. ;

Yassine, Hadi M. ;

Al Kuwari, Mohamed Ghaith ;

Al Romaihi, Hamad Eid ;

Al-Thani, Mohamed H. ;

Al Khal, Abdullatif ;

Bertollini, Roberto .

ECLINICALMEDICINE, 2021, 35

[2] Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate [J].

Addetia, Amin ;

Crawford, Katharine H. D. ;

Dingens, Adam ;

Zhu, Haiying ;

Roychoudhury, Pavitra ;

Huang, Meei-Li ;

Jerome, Keith R. ;

Bloom, Jesse D. ;

Greninger, Alexander L. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (11)

[3] Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies [J].

Breathnach, Aodhan Sean ;

Duncan, Christopher James Arthur ;

El Bouzidi, Kate ;

Hanrath, Aidan Taeke ;

Payne, Brendan Alexander Ingelby ;

Randell, Paul Anthony ;

Habibi, Maximillian Shahin ;

Riley, Peter Andrew ;

Planche, Timothy David ;

Busby, John Samuel ;

Sudhanva, Malur ;

Pallett, Scott John Charles ;

Kelleher, William Peter .

JOURNAL OF INFECTION, 2021, 83 (02) :239-241

[4] Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection [J].

Cromer, Deborah ;

Juno, Jennifer A. ;

Khoury, David ;

Reynaldi, Arnold ;

Wheatley, Adam K. ;

Kent, Stephen J. ;

Davenport, Miles P. .

NATURE REVIEWS IMMUNOLOGY, 2021, 21 (06) :395-404

[5]

Dan, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1936(e927154), 10.1093/cid/ciaa1936, DOI 10.1093/CID/CIAA1936]

[6] Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection [J].

Dan, Jennifer M. ;

Mateus, Jose ;

Kato, Yu ;

Hastie, Kathryn M. ;

Yu, Esther Dawen ;

Faliti, Caterina E. ;

Grifoni, Alba ;

Ramirez, Sydney, I ;

Haupt, Sonya ;

Frazier, April ;

Nakao, Catherine ;

Rayaprolu, Vamseedhar ;

Rawlings, Stephen A. ;

Peters, Bjoern ;

Krammer, Florian ;

Simon, Viviana ;

Saphire, Erica Ollmann ;

Smith, Davey M. ;

Weiskopf, Daniela ;

Sette, Alessandro ;

Crotty, Shane .

SCIENCE, 2021, 371 (6529) :587-+

[7]

Federal Office of Public Health, VIR VAR OV

[8] SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) [J].

Hall, Victoria Jane ;

Foulkes, Sarah ;

Charlett, Andre ;

Atti, Ana ;

Monk, Edward J. M. ;

Simmons, Ruth ;

Wellington, Edgar ;

Cole, Michelle J. ;

Saei, Ayoub ;

Oguti, Blanche ;

Munro, Katie ;

Wallace, Sarah ;

Kirwan, Peter D. ;

Shrotri, Madhumita ;

Vusirikala, Amoolya ;

Rokadiya, Sakib ;

Kall, Meaghan ;

Zambon, Maria ;

Ramsay, Mary ;

Brooks, Tim ;

Brown, Colin S. ;

Chand, Meera A. ;

Hopkins, Susan .

LANCET, 2021, 397 (10283) :1459-1469

[9] Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study [J].

Hansen, Christian Holm ;

Michlmayr, Daniela ;

Gubbels, Sophie Madeleine ;

Molbak, Kare ;

Ethelberg, Steen .

LANCET, 2021, 397 (10280) :1204-1212

[10]

Harrington D., 2021, Clin Infect Dis, DOI [10.1093/cid/ciab014, DOI 10.1093/CID/CIAB014]

← 1 2 3 →